---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-040532"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:35:42.950356+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arrivent Biopharma reports FY 2023 net loss of $69.3M; cash runway into 2026 after $201M IPO

## Summary
- R&D expenses $64.9M in 2023, up from $30.4M in 2022 on increased furmonertinib trial spending.
- Net loss $69.3M vs $37.0M in prior year; cash & marketable securities $150.4M at Dec 31, 2023.
- Completed $201M IPO in Jan 2024; management expects operations funded into 2026.
- FDA granted Breakthrough Therapy Designation for furmonertinib in NSCLC with EGFR exon 20 ins.
- Proof-of-concept data for furmonertinib in PACC mutations expected in 2024.

## SEC filing metadata
- accession: 0001104659-24-040532
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/0001104659-24-040532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/tm249692d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-040532
- JSON: https://secwatch.observer/filing/0001104659-24-040532.json
- Plain text: https://secwatch.observer/filing/0001104659-24-040532.txt

## Key facts
- Earnings Releases
  ArriVent BioPharma, Inc. reported the full year ended December 31, 2023 results: net income Net loss was $69.3 million.
  - Period: the full year ended December 31, 2023
  - Net income: Net loss was $69.3 million
  - Result: reported results
  source text: ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/0001104659-24-040532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.